Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib versus dacarbazine in previously untreated BRAF V600-mutant advanced or metastatic melanoma
NL-OMON44057Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Dabrafenib with Dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started May 2011; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON44057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44057.